These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 11298142)

  • 1. Comparison of antimicrobial susceptibility test breakpoints of national societies.
    Degener JE; Phillips I
    Clin Microbiol Infect; 2001 Feb; 7(2):51-4. PubMed ID: 11298142
    [No Abstract]   [Full Text] [Related]  

  • 2. Validation of EUCAST zone diameter breakpoints against reference broth microdilution.
    Bengtsson S; Bjelkenbrant C; Kahlmeter G
    Clin Microbiol Infect; 2014 Jun; 20(6):O353-60. PubMed ID: 24118469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Harmonization of antimicrobial susceptibility testing breakpoints in Europe: implications for reporting intermediate susceptibility.
    Brown D; Macgowan A
    J Antimicrob Chemother; 2010 Feb; 65(2):183-5. PubMed ID: 19996143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. European standards for antibiotic susceptibility testing: towards a theoretical consensus.
    Baquero F
    Eur J Clin Microbiol Infect Dis; 1990 Jul; 9(7):492-5. PubMed ID: 2226478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EUCAST Definitive Document E.DEF 2.1, August 2000: Determination of antimicrobial susceptibility test breakpoints.
    European Committee for Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID)
    Clin Microbiol Infect; 2000 Oct; 6(10):570-2. PubMed ID: 11168058
    [No Abstract]   [Full Text] [Related]  

  • 6. Susceptibility testing of bacteria and fungi. Report from "the Norwegian Working Group on Antibiotics".
    Bergan T; Bruun JN; Digranes A; Lingaas E; Melby KK; Sander J
    Scand J Infect Dis Suppl; 1997; 103():1-36. PubMed ID: 9253777
    [No Abstract]   [Full Text] [Related]  

  • 7. MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from Europe: comparison of antibiotic susceptibilities between countries and centre types. MYSTIC Study Group (European centres only).
    Goossens H
    J Antimicrob Chemother; 2000 Sep; 46 Suppl T2():39-52. PubMed ID: 11065147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breakpoints for intravenously used cephalosporins in Enterobacteriaceae--EUCAST and CLSI breakpoints.
    Kahlmeter G
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():169-74. PubMed ID: 18154542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cefazolin and enterobacteriaceae: rationale for revised susceptibility testing breakpoints.
    Turnidge JD;
    Clin Infect Dis; 2011 Apr; 52(7):917-24. PubMed ID: 21427400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Clinical and Laboratory Standards Institute 2008 and 2010 guidelines in interpreting susceptibility of enterobacteriaceae isolates.
    Agrawal GN; Shevade SU
    Indian J Pathol Microbiol; 2014; 57(3):518-9. PubMed ID: 25118774
    [No Abstract]   [Full Text] [Related]  

  • 11. Performance of Vitek 2 for antimicrobial susceptibility testing of Enterobacteriaceae with Vitek 2 (2009 FDA) and 2014 CLSI breakpoints.
    Bobenchik AM; Deak E; Hindler JA; Charlton CL; Humphries RM
    J Clin Microbiol; 2015 Mar; 53(3):816-23. PubMed ID: 25540403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antimicrobial susceptibility in Chile 2012].
    Cifuentes-D M; Silva F; García P; Bello H; Briceño I; Calvo-A M; Labarca J;
    Rev Chilena Infectol; 2014 Apr; 31(2):123-30. PubMed ID: 24878900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Recommendations for the analysis of cumulated data in antimicrobial susceptibility in health institutions].
    Comité de Microbiología, Sociedad Chilena de Infectología
    Rev Chilena Infectol; 2010 Apr; 27(2):126-32. PubMed ID: 20556314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of antimicrobial pharmacokinetic/pharmacodynamic breakpoints with EUCAST and CLSI clinical breakpoints for Gram-positive bacteria.
    Asín E; Isla A; Canut A; Rodríguez Gascón A
    Int J Antimicrob Agents; 2012 Oct; 40(4):313-22. PubMed ID: 22921422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimicrobial resistance in gram-positive bacteria: the myth of the MIC. Minimum inhibitory concentration.
    Rapp RP
    Pharmacotherapy; 1999 Aug; 19(8 Pt 2):112S-119S; discussion 133S-137S. PubMed ID: 10456608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Do patient data really support the clinical and laboratory standards institute recommendation for lowering third-generation cephalosporin interpretive breakpoints?
    Tamma PD; Powers JH
    Clin Infect Dis; 2013 Aug; 57(4):624-5. PubMed ID: 23658433
    [No Abstract]   [Full Text] [Related]  

  • 17. A report from the committee on microbroth dilution antimicrobial susceptibility testing : issues in antimicrobial susceptibility testing of Haemophilus influenzae: a comparison of the Japanese Society of Chemotherapy lysed horse blood and the CLSI HTM broth microdilution methods.
    Yamaguchi K; Hirakata Y; Kobayashi I; Ikedo M; Ohno A
    J Infect Chemother; 2012 Feb; 18(1):134-43. PubMed ID: 21894455
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparison of the Phoenix automated system, the Etest method and broth microdilution in determining temocillin susceptibility of Enterobacteriaceae.
    Patel TA; Dilley R; Williams A; Vanstone GL; Balakrishnan I
    J Antimicrob Chemother; 2013 Jul; 68(7):1685-6. PubMed ID: 23416956
    [No Abstract]   [Full Text] [Related]  

  • 19. [Antimicrobial susceptibility testing in clinically relevant non-fermenting gram-negative bacilli: recommendations from the Antimicrobial Agents Subcommittee of the Sociedad Argentina de Bacteriología, Micología y Parasitología Clínicas, Asociación Argentina de Microbiología].
    Radice M; Marín M; Giovanakis M; Vay C; Almuzara M; Limansky A; Casellas JM; Famiglietti A; Quinteros M; Bantar C; Galas M; Kovensky Pupko J; Nicola F; Pasterán F; Soloaga R; Gutkind G
    Rev Argent Microbiol; 2011; 43(2):136-53. PubMed ID: 21731977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Who defines resistance? The clinical and economic impact of antimicrobial susceptibility testing breakpoints.
    Jorgensen JH
    Semin Pediatr Infect Dis; 2004 Apr; 15(2):105-8. PubMed ID: 15185194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.